CD28 and neoplasm: The effectiveness of CARs directed against an alternative T cell-specific antigen, CD7, a marker detected also in 30% of AML blasts, was described in the aforementioned study by You et al. The NK-92MI cell line, characterized by IL-2 independence, has been transduced with either monovalent and bivalent nanobodies CD7Nb-directed CAR constructs (CD7Nb/dCD7Nb-directed CD28.4-1BB.CD3ζ.CAR-NK-92MI) and both presented strong anti-tumor activity [67].